Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.

Mitran B, Thisgaard H, Rinne S, Dam JH, Azami F, Tolmachev V, Orlova A, Rosenström U.

Sci Rep. 2019 Nov 19;9(1):17086. doi: 10.1038/s41598-019-52914-y.

2.

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.

Garousi J, Huizing FJ, Vorobyeva A, Mitran B, Andersson KG, Leitao CD, Frejd FY, Löfblom J, Bussink J, Orlova A, Heskamp S, Tolmachev V.

Sci Rep. 2019 Oct 17;9(1):14907. doi: 10.1038/s41598-019-51445-w.

3.

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, Rinne SS, Puuvuori E, De Rosa M, Larhed M, Tolmachev V, Orlova A, Rosenström U.

Cancers (Basel). 2019 Sep 14;11(9). pii: E1371. doi: 10.3390/cancers11091371.

4.

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.

Ding H, Altai M, Rinne SS, Vorobyeva A, Tolmachev V, Gräslund T, Orlova A.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1168. doi: 10.3390/cancers11081168.

5.

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.

Oroujeni M, Abouzayed A, Lundmark F, Mitran B, Orlova A, Tolmachev V, Rosenström U.

Pharmaceutics. 2019 Aug 2;11(8). pii: E380. doi: 10.3390/pharmaceutics11080380.

6.

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.

Abouzayed A, Yim CB, Mitran B, Rinne SS, Tolmachev V, Larhed M, Rosenström U, Orlova A.

Pharmaceutics. 2019 Jul 23;11(7). pii: E358. doi: 10.3390/pharmaceutics11070358.

7.

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3.

Vorobyeva A, Schulga A, Konovalova E, Güler R, Löfblom J, Sandström M, Garousi J, Chernov V, Bragina O, Orlova A, Tolmachev V, Deyev SM.

Sci Rep. 2019 Jun 28;9(1):9405. doi: 10.1038/s41598-019-45795-8.

8.

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging.

Vorobyeva A, Schulga A, Rinne SS, Günther T, Orlova A, Deyev S, Tolmachev V.

Int J Mol Sci. 2019 Jun 21;20(12). pii: E3047. doi: 10.3390/ijms20123047.

9.

Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.

Liu H, Lindbo S, Ding H, Altai M, Garousi J, Orlova A, Tolmachev V, Hober S, Gräslund T.

Int J Oncol. 2019 Jul;55(1):309-319. doi: 10.3892/ijo.2019.4814. Epub 2019 May 28.

PMID:
31180549
10.

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

von Witting E, Garousi J, Lindbo S, Vorobyeva A, Altai M, Oroujeni M, Mitran B, Orlova A, Hober S, Tolmachev V.

Eur J Pharm Biopharm. 2019 Jul;140:109-120. doi: 10.1016/j.ejpb.2019.05.008. Epub 2019 May 10.

11.

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.

Int J Cancer. 2019 Dec 15;145(12):3347-3358. doi: 10.1002/ijc.32401. Epub 2019 May 23.

PMID:
31077356
12.

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.

Rosestedt M, Andersson KG, Rinne SS, Leitao CD, Mitran B, Vorobyeva A, Ståhl S, Löfblom J, Tolmachev V, Orlova A.

Sci Rep. 2019 May 1;9(1):6779. doi: 10.1038/s41598-019-43145-2.

13.

Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.

Vorobyeva A, Sсhulga A, Konovalova E, Güler R, Mitran B, Garousi J, Rinne S, Löfblom J, Orlova A, Deyev S, Tolmachev V.

Int J Oncol. 2019 Apr;54(4):1209-1220. doi: 10.3892/ijo.2019.4712. Epub 2019 Feb 11.

14.

Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.

Westerlund K, Vorobyeva A, Mitran B, Orlova A, Tolmachev V, Karlström AE, Altai M.

Biomaterials. 2019 May;203:73-85. doi: 10.1016/j.biomaterials.2019.02.012. Epub 2019 Feb 14.

15.

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.

Dahlsson Leitao C, Rinne SS, Mitran B, Vorobyeva A, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Int J Mol Sci. 2019 Mar 2;20(5). pii: E1080. doi: 10.3390/ijms20051080.

16.

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.

Rinne SS, Leitao CD, Mitran B, Bass TZ, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Sci Rep. 2019 Jan 24;9(1):655. doi: 10.1038/s41598-018-36827-w.

17.

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

Deyev S, Vorobyeva A, Schulga A, Proshkina G, Güler R, Löfblom J, Mitran B, Garousi J, Altai M, Buijs J, Chernov V, Orlova A, Tolmachev V.

Mol Pharm. 2019 Mar 4;16(3):995-1008. doi: 10.1021/acs.molpharmaceut.8b00922. Epub 2019 Feb 8.

PMID:
30608701
18.

Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.

Garousi J, Lindbo S, Borin J, von Witting E, Vorobyeva A, Oroujeni M, Mitran B, Orlova A, Buijs J, Tolmachev V, Hober S.

Eur J Pharm Biopharm. 2019 Jan;134:37-48. doi: 10.1016/j.ejpb.2018.11.004. Epub 2018 Nov 5.

19.

Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.

Mitran B, Andersson KG, Lindström E, Garousi J, Rosestedt M, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Oncol Rep. 2019 Jan;41(1):534-542. doi: 10.3892/or.2018.6792. Epub 2018 Oct 15.

PMID:
30320363
20.

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.

Altai M, Leitao CD, Rinne SS, Vorobyeva A, Atterby C, Ståhl S, Tolmachev V, Löfblom J, Orlova A.

Cells. 2018 Oct 11;7(10). pii: E164. doi: 10.3390/cells7100164.

21.

Basic and practical concepts of radiopharmaceutical purification methods.

Molavipordanjani S, Tolmachev V, Hosseinimehr SJ.

Drug Discov Today. 2019 Jan;24(1):315-324. doi: 10.1016/j.drudis.2018.09.018. Epub 2018 Sep 29. Review.

PMID:
30278224
22.

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.

Oroujeni M, Garousi J, Andersson KG, Löfblom J, Mitran B, Orlova A, Tolmachev V.

Cells. 2018 Sep 18;7(9). pii: E141. doi: 10.3390/cells7090141.

23.

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.

24.

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.

Altai M, Liu H, Ding H, Mitran B, Edqvist PH, Tolmachev V, Orlova A, Gräslund T.

J Control Release. 2018 Oct 28;288:84-95. doi: 10.1016/j.jconrel.2018.08.040. Epub 2018 Aug 30.

PMID:
30172673
25.

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

Orlova A, Bass TZ, Rinne SS, Leitao CD, Rosestedt M, Atterby C, Gudmundsdotter L, Frejd FY, Löfblom J, Tolmachev V, Ståhl S.

Mol Pharm. 2018 Aug 6;15(8):3394-3403. doi: 10.1021/acs.molpharmaceut.8b00393. Epub 2018 Jul 25.

PMID:
29995421
26.

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Vorobyeva A, Bragina O, Altai M, Mitran B, Orlova A, Shulga A, Proshkina G, Chernov V, Tolmachev V, Deyev S.

Contrast Media Mol Imaging. 2018 Jun 6;2018:6930425. doi: 10.1155/2018/6930425. eCollection 2018.

27.

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.

Vorobyeva A, Westerlund K, Mitran B, Altai M, Rinne S, Sörensen J, Orlova A, Tolmachev V, Karlström AE.

Sci Rep. 2018 Jun 25;8(1):9643. doi: 10.1038/s41598-018-27886-0.

28.

Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga.

Lindbo S, Garousi J, Mitran B, Vorobyeva A, Oroujeni M, Orlova A, Hober S, Tolmachev V.

Mol Pharm. 2018 Jul 2;15(7):2674-2683. doi: 10.1021/acs.molpharmaceut.8b00204. Epub 2018 Jun 20.

PMID:
29865791
29.

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.

Oroujeni M, Andersson KG, Steinhardt X, Altai M, Orlova A, Mitran B, Vorobyeva A, Garousi J, Tolmachev V, Löfblom J.

Amino Acids. 2018 Aug;50(8):981-994. doi: 10.1007/s00726-018-2571-1. Epub 2018 May 4.

30.

Molecular design of radiocopper-labelled Affibody molecules.

Tolmachev V, Grönroos TJ, Yim CB, Garousi J, Yue Y, Grimm S, Rajander J, Perols A, Haaparanta-Solin M, Solin O, Ferdani R, Orlova A, Anderson CJ, Karlström AE.

Sci Rep. 2018 Apr 25;8(1):6542. doi: 10.1038/s41598-018-24785-2.

31.

Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse.

Nordling S, Brännström J, Carlsson F, Lu B, Salvaris E, Wanders A, Buijs J, Estrada S, Tolmachev V, Cowan PJ, Lorant T, Magnusson PU.

Sci Rep. 2018 Mar 26;8(1):5220. doi: 10.1038/s41598-018-21463-1.

32.

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology.

Krasniqi A, D'Huyvetter M, Devoogdt N, Frejd FY, Sörensen J, Orlova A, Keyaerts M, Tolmachev V.

J Nucl Med. 2018 Jun;59(6):885-891. doi: 10.2967/jnumed.117.199901. Epub 2018 Mar 15. Review.

33.

Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.

Honarvar H, Calce E, Doti N, Langella E, Orlova A, Buijs J, D'Amato V, Bianco R, Saviano M, Tolmachev V, De Luca S.

Sci Rep. 2018 Feb 14;8(1):2998. doi: 10.1038/s41598-018-21283-3.

34.

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle.

Westerlund K, Altai M, Mitran B, Konijnenberg M, Oroujeni M, Atterby C, de Jong M, Orlova A, Mattsson J, Micke P, Karlström AE, Tolmachev V.

J Nucl Med. 2018 Jul;59(7):1092-1098. doi: 10.2967/jnumed.118.208348. Epub 2018 Feb 9.

35.

Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018.

Binzel K, Adelaja A, Wright CL, Scharre D, Zhang J, Knopp MV, Teoh EJ, Bottomley D, Scarsbrook A, Payne H, Afaq A, Bomanji J, van As N, Chua S, Hoskin P, Chambers A, Cook GJ, Warbey VS, Chau A, Ward P, Miller MP, Stevens DJ, Wilson L, Gleeson FV, Scheidhauer K, Seidl C, Autenrieth M, Bruchertseifer F, Apostolidis C, Kurtz F, Horn T, Pfob C, Schwaiger M, Gschwend J, D'Alessandria C, Morgenstern A, Uprimny C, Kroiss A, Decristoforo C, von Guggenberg E, Nilica B, Horninger W, Virgolini I, Rasul S, Poetsch N, Woehrer A, Preusser M, Mitterhauser M, Wadsak W, Widhalm G, Mischkulnig M, Hacker M, Traub-Weidinger T, Wright CL, Binzel K, Wuthrick EJ, Miller ED, Maniawski P, Zhang J, Knopp MV, Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L, Mairinger S, Filip T, Sauberer M, Flunkert S, Wanek T, Stanek J, Okamura N, Langer O, Kuntner C, Fornito MC, Balzano R, Di Martino V, Cacciaguerra S, Russo G, Seifert D, Kleinova M, Cepa A, Ralis J, Hanc P, Lebeda O, Mosa M, Vandenberghe S, Mikhaylova E, Borys D, Viswanath V, Stockhoff M, Efthimiou N, Caribe P, Van Holen R, Karp JS, Binzel K, Zhang J, Wright CL, Maniawski P, Knopp MV, Haller PM, Farhan C, Piackova E, Jäger B, Knoll P, Kiss A, Podesser BK, Wojta J, Huber K, Mirzaei S, Traxl A, Komposch K, Glitzner E, Wanek T, Mairinger S, Sibilia M, Langer O, Fornito MC, Russello M, Russo G, Balzano R, Sorko S, Gallowitsch HJ, Kohlfuerst S, Matschnig S, Rieser M, Sorschag M, Lind P, Ležaič L, Rep S, Žibert J, Frelih N, Šuštar S, Binzel K, Adelaja A, Wright CL, Scharre D, Zhang J, Knopp MV, Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, Kulkarni HR, Fornito MC, Cacciaguerra S, Balzano R, Di Martino GV, Russo G, Thomson WH, Kudlacek M, Karik M, Farhan C, Rieger H, Pokieser W, Glaser K, Mirzaei S, Petz V, Tugendsam C, Buchinger W, Schmoll-Hauer B, Schenk IP, Rudolph K, Krebs M, Zettinig G, Zoufal V, Wanek T, Krohn M, Mairinger S, Stanek J, Sauberer M, Filip T, Pahnke J, Langer O, Weitzer F, Pernthaler B, Salamon S, Aigner R, Koranda P, Henzlová L, Kamínek M, Váchalová M, Bachleda P, Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom JN, Orlova A, Tolmachev V, Decristoforo C, Kaeopookum P, Summer D, Orasch T, Lechner B, Petrik M, Novy Z, Rangger C, Haas H, Decristoforo C.

EJNMMI Res. 2018 Jan 23;8(Suppl 1):5. doi: 10.1186/s13550-017-0354-4. No abstract available.

36.

Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.

Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom J, Orlova A, Tolmachev V, Decristoforo C.

Mol Pharm. 2018 Jan 2;15(1):175-185. doi: 10.1021/acs.molpharmaceut.7b00787. Epub 2017 Dec 1.

37.

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.

Garousi J, Lindbo S, Mitran B, Buijs J, Vorobyeva A, Orlova A, Tolmachev V, Hober S.

Sci Rep. 2017 Nov 7;7(1):14780. doi: 10.1038/s41598-017-15366-w.

38.

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA.

Tolmachev V, Yim CB, Rajander J, Perols A, Karlström AE, Haaparanta-Solin M, Grönroos TJ, Solin O, Orlova A.

Contrast Media Mol Imaging. 2017 Feb 28;2017:8565802. doi: 10.1155/2017/8565802. eCollection 2017.

39.

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.

Mitran B, Thisgaard H, Rosenström U, Dam JH, Larhed M, Tolmachev V, Orlova A.

Contrast Media Mol Imaging. 2017 Aug 10;2017:6873684. doi: 10.1155/2017/6873684. eCollection 2017.

40.

Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.

Rosestedt M, Andersson KG, Mitran B, Rinne SS, Tolmachev V, Löfblom J, Orlova A, Ståhl S.

Int J Oncol. 2017 Dec;51(6):1765-1774. doi: 10.3892/ijo.2017.4152. Epub 2017 Oct 11.

PMID:
29039474
41.

Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.

Lindbo S, Garousi J, Mitran B, Altai M, Buijs J, Orlova A, Hober S, Tolmachev V.

J Nucl Med. 2018 Jan;59(1):93-99. doi: 10.2967/jnumed.117.197202. Epub 2017 Sep 1.

42.

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.

Garousi J, Andersson KG, Dam JH, Olsen BB, Mitran B, Orlova A, Buijs J, Ståhl S, Löfblom J, Thisgaard H, Tolmachev V.

Sci Rep. 2017 Jul 20;7(1):5961. doi: 10.1038/s41598-017-05700-7.

43.

Pretargeted Imaging and Therapy.

Altai M, Membreno R, Cook B, Tolmachev V, Zeglis BM.

J Nucl Med. 2017 Oct;58(10):1553-1559. doi: 10.2967/jnumed.117.189944. Epub 2017 Jul 7. Review.

44.

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, Sörensen J.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1337-1346. doi: 10.1007/s00259-017-3650-3. Epub 2017 Mar 6.

45.

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.

Bass TZ, Rosestedt M, Mitran B, Frejd FY, Löfblom J, Tolmachev V, Ståhl S, Orlova A.

Sci Rep. 2017 Feb 23;7:43118. doi: 10.1038/srep43118.

46.

Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors.

Honarvar H, Müller C, Cohrs S, Haller S, Westerlund K, Karlström AE, van der Meulen NP, Schibli R, Tolmachev V.

Nucl Med Biol. 2017 Feb;45:15-21. doi: 10.1016/j.nucmedbio.2016.10.004. Epub 2016 Oct 18.

PMID:
27837664
47.

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.

Andersson KG, Oroujeni M, Garousi J, Mitran B, Ståhl S, Orlova A, Löfblom J, Tolmachev V.

Int J Oncol. 2016 Dec;49(6):2285-2293. doi: 10.3892/ijo.2016.3721. Epub 2016 Oct 5.

48.

Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.

Garousi J, Lindbo S, Honarvar H, Velletta J, Mitran B, Altai M, Orlova A, Tolmachev V, Hober S.

Bioconjug Chem. 2016 Nov 16;27(11):2678-2688. Epub 2016 Oct 27.

PMID:
27740752
49.

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.

Altai M, Liu H, Orlova A, Tolmachev V, Gräslund T.

Int J Oncol. 2016 Sep;49(3):1185-94. doi: 10.3892/ijo.2016.3614. Epub 2016 Jul 6.

PMID:
27573289
50.

Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.

Garousi J, Honarvar H, Andersson KG, Mitran B, Orlova A, Buijs J, Löfblom J, Frejd FY, Tolmachev V.

Mol Pharm. 2016 Nov 7;13(11):3676-3687. Epub 2016 Sep 27.

PMID:
27529191

Supplemental Content

Loading ...
Support Center